Abstract: The present disclosure, relates, in general to methods for improving adverse events in subjects receiving treatment with an anti-CD30 antibody drug conjugate, optionally also receiving accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.
Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
Type:
Application
Filed:
April 7, 2022
Publication date:
September 22, 2022
Applicants:
Bristol-Myers Squibb Company, Seattle Genetics, Inc.
Inventors:
Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER
Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
Type:
Application
Filed:
July 29, 2020
Publication date:
February 18, 2021
Applicant:
SEATTLE GENETICS, INC.
Inventors:
May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.
Type:
Application
Filed:
April 16, 2020
Publication date:
January 21, 2021
Applicant:
Seattle Genetics, Inc.
Inventors:
Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.
Type:
Application
Filed:
February 14, 2020
Publication date:
January 14, 2021
Applicant:
Seattle Genetics, Inc.
Inventors:
Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.
Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
Abstract: The present invention provides a method for removing cysteine caps from antibodies and re-capping the antibodies with cysteine molecules. The methods include, inter alia, culturing a host cell comprising a protein molecule having at least one capped engineered cysteine residue, and contacting the cell culture with cystine. Dissolved oxygen levels can be manipulated in the cell culture to further enhance the removal and re-capping process.
Type:
Grant
Filed:
November 6, 2017
Date of Patent:
November 10, 2020
Assignee:
Seattle Genetics, Inc.
Inventors:
Swapnil Bhargava, Cheng-Wei Aaron Chen, Matthew J. Leith
Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
Type:
Grant
Filed:
July 10, 2019
Date of Patent:
October 20, 2020
Assignee:
Seattle Genetics Inc.
Inventors:
Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
Type:
Grant
Filed:
January 20, 2017
Date of Patent:
September 29, 2020
Assignee:
SEATTLE GENETICS, INC.
Inventors:
May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include mono clonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. In some embodiments, the present invention provides an antibody having a heavy chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 63 and having a light chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 64.
Type:
Application
Filed:
January 14, 2020
Publication date:
September 3, 2020
Applicant:
Seattle Genetics, Inc.
Inventors:
Ana Paula Galvao da Silva, Julie DeSander, Jeffrey Behrens, Darius Ghaderi, Mai Zhang, Kristan Meetze
Abstract: Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.
Type:
Application
Filed:
November 17, 2017
Publication date:
August 6, 2020
Applicant:
Seattle Genetics, Inc.
Inventors:
Jillian M. Prendergast, David A. Eavarone, Patricia Rao
Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
Abstract: This invention relates to treatment of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Specifically, the disclosure provides a method of treating a subject having DLBCL or FL, the method comprising administering to the subject a drug combination consisting essentially of a CD19 antibody drug conjugate (CD19-ADC), and rituximab, cyclophosphamide, doxorubicin, and prednisone (RCHP).